OTCMKTS:MATN - Mateon Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.17
+0.30 (1.20%)

This chart shows the closing price for MATN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mateon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MATN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MATN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Mateon Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.17.

This chart shows the closing price for MATN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Mateon Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/7/2020Litchfield Hills ResearchInitiated CoverageBuy$3.00
4/22/2019HC WainwrightReiterated RatingHold
8/17/2018HC WainwrightDowngradeBuy ➝ Neutral
4/18/2018HC WainwrightSet Price TargetBuy$1.00
11/22/2017HC WainwrightReiterated RatingBuy$1.00
8/1/2017Maxim GroupReiterated RatingHold
6/7/2017Maxim GroupReiterated RatingHold
5/16/2017Maxim GroupDowngradeBuy ➝ Hold$2.00
4/27/2017Maxim GroupSet Price TargetBuy$2.00
4/20/2017Roth CapitalInitiated CoverageBuy ➝ Buy$2.00
4/18/2017Maxim GroupReiterated RatingBuy$2.00
3/16/2017Maxim GroupReiterated RatingBuy$2.00
3/13/2017HC WainwrightInitiated CoverageBuy$2.00
3/13/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$2.00
1/27/2017Maxim GroupInitiated CoverageBuy$2.00
(Data available from 12/9/2016 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Mateon Therapeutics logo
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Read More

Today's Range

Now: $0.17
Low: $0.15
High: $0.19

50 Day Range

MA: $0.13
Low: $0.11
High: $0.18

52 Week Range

Now: $0.17
Low: $0.13
High: $0.38

Volume

231,571 shs

Average Volume

338,444 shs

Market Capitalization

$15.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Mateon Therapeutics?

The following sell-side analysts have issued stock ratings on Mateon Therapeutics in the last twelve months:
View the latest analyst ratings for MATN.

What is the current price target for Mateon Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Mateon Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mateon Therapeutics in the next year.
View the latest price targets for MATN.

What is the current consensus analyst rating for Mateon Therapeutics?

Mateon Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MATN.

How do I contact Mateon Therapeutics' investor relations team?

Mateon Therapeutics' physical mailing address is 29397 AGOURA ROAD SUITE 107, AGUORA HILLS CA, 91301. The biopharmaceutical company's listed phone number is 650-635-7000 and its investor relations email address is [email protected] The official website for Mateon Therapeutics is www.mateon.com.